These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 22249792)

  • 1. Cyclooxygenase-2 and human epidermal growth factor receptor type 2 (HER-2) expression simultaneously in invasive and in situ breast ductal carcinoma.
    Lucarelli AP; Martins MM; Montor W; Oliveira V; Galvão MA; Piato S
    Sao Paulo Med J; 2011 Dec; 129(6):371-9. PubMed ID: 22249792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in situ, and adjacent normal epithelium.
    Oliveira VM; Piato S; Silva MA
    Breast Cancer Res Treat; 2006 Feb; 95(3):235-41. PubMed ID: 16322898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical COX-2 overexpression correlates with HER-2/neu overexpression in invasive breast carcinomas: a pilot study.
    Çiriş IM; Bozkurt KK; Başpinar S; Kapucuoğlu FN
    Pathol Res Pract; 2011 Mar; 207(3):182-7. PubMed ID: 21371829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical significance of expression of PI3Kp110α in breast cancer].
    Xiong Y; Si JW; Li D; Wang Y; Qu LL; Zhang H; Zhang B; Li T
    Zhonghua Zhong Liu Za Zhi; 2016 Oct; 38(10):743-749. PubMed ID: 27784457
    [No Abstract]   [Full Text] [Related]  

  • 5. [Aromatase expression in invasive and in situ ductal carcinoma present in the same breast].
    Oliveira VM; Ribeiro Lde S; Rossi LM; Silva MA; Aldrighi JM; Bagnoli F; Rinaldi JF; Aoki T
    Rev Assoc Med Bras (1992); 2009; 55(6):651-5. PubMed ID: 20191218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].
    Yang M; Xu SP; Ao QL
    Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The status of cyclooxygenase-2 expression in ductal carcinoma in situ lesions and invasive breast cancer correlates to cyclooxygenase-2 expression in normal breast tissue.
    Leo C; Faber S; Hentschel B; Höckel M; Horn LC
    Ann Diagn Pathol; 2006 Dec; 10(6):327-32. PubMed ID: 17126249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
    Steinman S; Wang J; Bourne P; Yang Q; Tang P
    Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COX-2, p16 and Ki67 expression in DCIS, microinvasive and early invasive breast carcinoma with extensive intraductal component.
    Bartova M; Ondrias F; Muy-Kheng T; Kastner M; Singer Ch; Pohlodek K
    Bratisl Lek Listy; 2014; 115(7):445-51. PubMed ID: 25077370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein kinase C alpha expression in normal breast, ductal carcinoma in situ and invasive ductal carcinoma.
    Ainsworth PD; Winstanley JH; Pearson JM; Bishop HM; Garrod DR
    Eur J Cancer; 2004 Oct; 40(15):2269-73. PubMed ID: 15454252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade.
    Papantoniou V; Sotiropoulou E; Valsamaki P; Tsaroucha A; Sotiropoulou M; Ptohis N; Stipsanelli A; Dimitrakakis K; Marinopoulos S; Tsiouris S; Antsaklis A
    Breast Cancer; 2011 Oct; 18(4):286-91. PubMed ID: 20143189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated expression of cyclooxygenase-2 in breast cancer and ductal carcinoma in situ has no correlation with established prognostic markers.
    Ranger GS; Jewell A; Thomas V; Mokbel K
    J Surg Oncol; 2004 Nov; 88(2):100-3. PubMed ID: 15499599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ.
    Boland GP; Butt IS; Prasad R; Knox WF; Bundred NJ
    Br J Cancer; 2004 Jan; 90(2):423-9. PubMed ID: 14735188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR; Abd-Elwahed SR; Abdulwahed AR
    Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bax protein expression in DCIS of the breast in relation to invasive ductal carcinoma and other molecular markers.
    Rehman S; Crow J; Revell PA
    Pathol Oncol Res; 2000; 6(4):256-63. PubMed ID: 11173657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
    Park K; Han S; Kim HJ; Kim J; Shin E
    Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lectin histochemistry reveals SNA as a prognostic carbohydrate-dependent probe for invasive ductal carcinoma of the breast: a clinicopathological and immunohistochemical auxiliary tool.
    dos-Santos PB; Zanetti JS; Vieira-de-Mello GS; Rêgo MB; Ribeiro-Silva A A; Beltrão EI
    Int J Clin Exp Pathol; 2014; 7(5):2337-49. PubMed ID: 24966944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression.
    Suzuki J; Chen YY; Scott GK; Devries S; Chin K; Benz CC; Waldman FM; Hwang ES
    Clin Cancer Res; 2009 May; 15(9):3163-71. PubMed ID: 19383825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations of ER, PR, HER-2/neu, and P53 protein expression in ductal breast carcinomas and clinical implications.
    Liu C; Zhang H; Shuang C; Lu Y; Jin F; Xu H; Lu P
    Med Oncol; 2010 Sep; 27(3):747-52. PubMed ID: 19657752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telomerase activity in ductal carcinoma in situ of the breast.
    Shpitz B; Zimlichman S; Zemer R; Bomstein Y; Zehavi T; Liverant S; Bernehim J; Kaufman Z; Klein E; Shapira Y; Klein A
    Breast Cancer Res Treat; 1999 Nov; 58(1):65-9. PubMed ID: 10634519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.